Pre-clinical studies indicate that myeloperoxidase (MPO) and eosinophil peroxidase (EPO) are non-toxic, non-irritating, non-genotoxic, and non-sensitizing in various formulations, including solutions, gels, and sprays. The unique microbicidal mechanisms of MPO and EPO systems suggest a high margin of safety to support a wide variety of indications. MPO resistance induction studies found no resistance development in clinically important bacterial isolates.

Results of in vitro and in vivo studies

In vitro studies by Exoxemis show rapid microbicidal activity of MPO against clinically significant antibiotic-resistant and antibiotic-susceptible strains of gram-negative and gram-positive bacteria, spores, fungi, and viruses: Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended spectrum beta-lactamase producers (ESBL), mucoid strains, and multidrug-resistant organisms.

In vivo studies by Exoxemis have demonstrated microbicidal activity in support of preventing and treating infectious diseases. In addition to broad spectrum and rapid cidal activity, MPO and its formulations have been shown, in early studies, to be both safe and effective.

A comparison of MPO system to antibiotics for irrigation of implant material

Residual bacteria at the site of implant surgery can lead to acute and delayed infection. Recent studies conducted by Exoxemis clearly demonstrated that the MPO enzyme system rapidly and completely kills residual S. aureus, even in the presence of implant material. Antibiotic solutions traditionally used in the clinic failed to do so, and in fact, showed re-growth of the initial inoculum. Future studies are needed to evaluate the efficacy of the MPO enzyme system against other pathogens and implant materials, and in preventing contamination, biofilm formation, and subsequent infection. Learn more >>